Your browser doesn't support javascript.
loading
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Kollmorgen, Gwendlyn; Palme, Klara; Seidl, Annette; Scheiblich, Stefan; Birzele, Fabian; Wilson, Sabine; Clemens, Christian; Voss, Edgar; Kaufmann, Martin; Hirzel, Klaus; Rieder, Natascha; Krippendorff, Ben-Fillippo; Herting, Frank; Niederfellner, Gerhard.
Afiliação
  • Kollmorgen G; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany. gwendlyn.kollmorgen@roche.com.
  • Palme K; Early Development & Rare Reagents, Roche Diagnostics GmbH, Munich, Germany. gwendlyn.kollmorgen@roche.com.
  • Seidl A; Pathology and Tissue Analytics, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany. gwendlyn.kollmorgen@roche.com.
  • Scheiblich S; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Birzele F; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Wilson S; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Clemens C; Bioinformatics, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Voss E; Pharmaceutical Sciences, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Kaufmann M; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Hirzel K; Discovery Oncology, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Rieder N; Immunoassay Development Oncological Diseases, Roche Diagnostics GmbH, Munich, Germany.
  • Krippendorff BF; Early Development & Rare Reagents, Roche Diagnostics GmbH, Munich, Germany.
  • Herting F; Pathology and Tissue Analytics, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Munich, Germany.
  • Niederfellner G; Pharmaceutical Sciences, Pharmaceutical Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.
Sci Rep ; 7(1): 18086, 2017 12 22.
Article em En | MEDLINE | ID: mdl-29273809
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Imunotoxinas / Imunoconjugados / Proliferação de Células / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Imunotoxinas / Imunoconjugados / Proliferação de Células / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article